Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SoMe: sorafenib plus cisplatin and pemetrexed in malignant pleural mesothelioma
2007-005894-77Phase 2Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of sorafenib in pleural mesothelioma (2 arms), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoints: Efficacy of sorafenib in combination with cisplatin plus pemetrexed and Safety of sorafenib in combination with cisplatin plus pemetrexed. Started Jan 2008; status: completed.
02
Drugs
sorafenib
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2007-005894-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005894-77.